Mylan Must Shell Out $18M To Sunovion In Xopenex Patent Suit
A Delaware federal jury on Friday awarded $18 million to Sunovion Pharmaceuticals Inc., finding that Mylan Pharmaceuticals Inc. had willfully infringed five patents when it manufactured and sold a generic version...To view the full article, register now.
Already a subscriber? Click here to view full article